Cephadar Suspension
Cephalexin
250mg/5ml
Dar Al Dawa Development & Investment Co. Ltd.
| Pack size | 100ml Bottle |
|---|---|
| Dispensing mode | POM |
| Source | JORDAN |
| Agent | AL MUFID PHARMACEUTICALS |
| Retail Price | 12.00 AED |
Available as:
Indications
Cephadar Suspension is used for:
Pneumonia, Otitis media, Bacterial endocarditis, Streptococcal pharyngitis, Cellulitis, Respiratory tract infections, Urinary tract infections, Bone and Joint Infections, Genitourinary tract infections, Acute prostatitis
Adult Dose
Oral
Bone and joint infections; Respiratory tract infections, Genitourinary Tract Infections, Otitis Media
Adults
1 to 4 g/day in divided doses.
Usual dose is 250 mg every 6 hours.
Streptococcal pharyngitis, skin and skin structure infections, uncomplicated cystitis, cellulitis and mastitis
>15 years 500 mg every 12 hours.
Child Dose
Children
25 to 50 mg/kg/day q12h
For streptococcal pharyngitis in patients >1year old and for skin and skin structure infections, divide total daily dose and give every 12 hours.
In sever infections, 75–100 mg/kg/day for bone and joint, otitis media or severe infections q6–8h
Beta-hemolytic streptococcal infections: Continue treatment for at least 10 days.
Renal Dose
Renal impairment:
CrCl (ml/min)
40-50 Max: 3 g daily.
10-40 Max: 1.5 g daily.
<10 Max: 750 mg daily.
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contra Indications
Hypersensitivity to cephalosporins.
Precautions
Hypersensitivity to penicillins; pseudomembranous colitis; renal failure; pregnancy and lactation.
Lactation: Drug excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy
There are no adequate and well-controlled studies
Available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Animal data
Animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (MRHD) based on body surface area during organogenesis revealed no evidence of harm to the fetus; estimated background risk of major birth defects and miscarriage for indicated population is unknown
Lactation
Data from a published clinical lactation study reports that cephalexin is present in human milk; relative infant dose (RID) is considered to be <1% of maternal weight adjusted dose; there are no data on effects of cephalexin on breastfed child or on milk production
Development of health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition
Interactions
Concurrent use w/ metfromin may result to fatal lactic acidosis. May enhance the anticoagulant effect of vit K antagonists (e.g. warfarin). Increased risk of nephrotoxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide) and other potentially nephrotoxic antibiotics (e.g. aminoglycosides, polymyxin, colistin). Prothrombin time may be prolonged when used concomitantly w/ oral anticoagulants. May reduce the effects of OCs. Hypokalaemia may result from concomitant use of cefalexin and cytotoxic drugs for leukaemia. Uricosuric drugs (e.g. probenecid) may suppress renal excretion, resulting to increased plasma levels of cefalexin. May diminish the therapeutic effect of Na picosulfate, BCG and typhoid vaccine. May reduce serum level w/ multivitamins/minerals.
Adverse Effects
Side effects of Cephalexin :
GI disturbances (e.g. nausea, vomiting, diarrhoea, abdominal discomfort), dyspepsia; allergic reactions (e.g. rash urticaria, angioedema); genital and anal pruritus, genital candidiasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis and joint disorders; eosinophilia, neutropenia, thrombocytopenia, haemolytic anaemia, slightly elevated AST and ALT. Rarely, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis; cholestatic jaundice, transient hepatitis.
Potentially Fatal: Anaphylactic reactions; nephrotoxicity.
Mechanism of Action
Cefalexin binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Note
Cephadar 250mg/5ml Suspension manufactured by Dar Al Dawa Development & Investment Co. Ltd.. Its generic name is Cephalexin. Cephadar is availble in United Arab Emirates.
Farmaco UAE drug index information on Cephadar Suspension is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Cephalexin :
Suspension
Sporidex
250mg/5ml
Ranbaxy Laboratories Limited
Capsules (Hard Gelatin)
Sporidex
500mg
Ranbaxy Laboratories Limited
Capsules (Hard Gelatin)
Sporidex
250mg
Ranbaxy Laboratories Limited
Suspension
Sporidex
125mg/5ml
Ranbaxy Laboratories Limited
Tablets / Film-coated
Ospexin
500mg
Sandoz GmbH